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Abstract
Summary Strontium ranelate appears to influence more
than alendronate distal tibia bone microstructure as assessed
by high-resolution peripheral quantitative computed tomog-
raphy (HR-pQCT), and biomechanically relevant parame-
ters as assessed by micro-finite element analysis (μFEA),
over 2 years, in postmenopausal osteoporotic women.
Introduction Bone microstructure changes are a target in
osteoporosis treatment to increase bone strength and reduce
fracture risk.
Methods Using HR-pQCT, we investigated the effects on
distal tibia and radius microstructure of strontium ranelate
(SrRan; 2 g/day) or alendronate (70 mg/week) for 2 years in
postmenopausal osteoporotic women. This exploratory
randomized, double-blind trial evaluated HR-pQCT and
FEA parameters, areal bone mineral density (BMD), and
bone turnover markers.
Results In the intention-to-treat population (n=83, age: 64±
8 years; lumbar T-score: −2.8±0.8 [DXA]), distal tibia
Cortical Thickness (CTh) and Density (DCort), and cancel-
lous BV/TV increased by 6.3%, 1.4%, and 2.5%, respec-
tively (all P<0.005), with SrRan, but not with alendronate
(0.9%, 0.4%, and 0.8%, NS) (P<0.05 for all above between-
group differences). Difference for CTh evaluated with a
distance transformation method was close to significance
(P=0.06). The estimated failure load increased with SrRan
(+2.1%, P<0.005), not with alendronate (−0.6%, NS)
(between-group difference, P<0.01). Cortical stress was
lower with SrRan (P<0.05); both treatments decreased
trabecular stress. At distal radius, there was no between-
group difference other than DCort (P<0.05). Bone
turnover markers decreased with alendronate; bALP
increased (+21%) and serum-CTX-I decreased (−1%) after
2 years of SrRan (between-group difference at each time
point for both markers, P<0.0001). Both treatments were
well tolerated.
Conclusions Within the constraints of HR-pQCT method,
and while a possible artefactual contribution of strontium
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cannot be quantified, SrRan appeared to influence distal
tibia bone microstructure and FEA-determined biomechan-
ical parameters more than alendronate. However, the
magnitude of the differences is unclear and requires
confirmation with another method.
Keywords Alendronate . Finite elements analysis . HR-
pQCT.Microstructure . Osteoporosis . Strontium ranelate
Introduction
Fragility fractures result from a low bone resistance to an
external force [1, 2]. Bone strength is determined by
material and structural properties [1, 2]. There is a variety
of new techniques available in bone imaging for the
determination of bone microstructure [3, 4], providing an
increasing amount of evidence for the links between bone
strength and structure in osteoporosis. High-resolution
peripheral quantitative computed tomography (HR-pQCT)
gives three-dimensional datasets providing estimate of bone
geometry, cortical and trabecular structures [5, 6]. This
technique has confirmed that an impairment in trabecular
and/or cortical structures is associated with increased risk
for vertebral and non-vertebral fracture in postmenopausal
women in case-control studies [7–11] HR-pQCT also allows
for a non-invasive quantification of bone strength and
mechanical features of cortical and trabecular bone by using
finite element analysis (FEA) [12] Failure load predicted by
a linear FE model is consistent with experimental testing
[13]. Moreover, radius [14, 15] and radius and tibia [16]
bone mechanical properties as assessed by FEA are
associated with fragility fracture independently of bone
mineral density (DMD) or microstructure in postmenopaus-
al women. HR-pQCT images can be used either as
continuous models with a gray-scale voxel conversion to
modulus of elasticity, similarly to clinical CT data, or as
binary images using fixed homogeneous material proper-
ties. The first model implicitly takes into account partial
volume effects and changes in tissue mineralization, which
may result from the osteoporosis treatment, whereas the
second model considers changes in bone microstructure
independently of material effects. Both models provide
good estimate of distal radius apparent strength, even
though the correlation is slightly higher with scaled tissue
modulus than homogeneous modulus models (R2=0.983
versus R2=0.972, P<0.05, n=31) [14].
The improvement of trabecular and cortical structure is a
therapeutic target in osteoporosis since this may increase
bone strength and reduce fracture risk. The study described
herein was designed to explore the effects of a 2-year
treatment with strontium ranelate, as compared to alendro-
nate, on bone microstructure in postmenopausal women
with osteoporosis. Strontium ranelate reduces the risk of
vertebral and non-vertebral fractures in postmenopausal
women with osteoporosis [15, 16]. Histomorphometric and
micro-CT analyses of bone biopsies of strontium ranelate-
treated women have suggested improvements in trabecular
and cortical microstructure [17]. The bone resorption
inhibitor alendronate has anti-fracture efficacy [18]. While
histomorphometric analyses with alendronate indicate
maintenance of trabecular and cortical structure, they failed
to detect any improvement [19]. Our study involved HR-
pQCT analyses in treated women on both distal tibia and
distal radius, including FEA at the tibia as well as
evaluation of areal BMD of the spine and the hip by
DXA, and of bone turnover markers (bone alkaline
phosphatase [b-ALP] for bone formation, and serum C-
telopeptide cross-links of type-1 collagen [S-CTX-I] for
bone resorption). The preplanned interim 1-year analysis of
the here discussed study has been previously published
[20], and this report presents now the final analysis of the
whole study.
Methods
Study design
The study design has extensively been described previously
[20]. Briefly, this randomized, double-blind, double-
dummy, 2-year-long trial was carried out in eight centers
across four countries (Australia, France, Germany, and
Switzerland). Ambulatory Caucasian postmenopausal
women, aged 50 years and over, were included if they
had a lumbar (L1-L4), femoral neck, or total hip T-score of
less than −2.5, as assessed by DXA. Exclusion criteria were
body mass index (BMI) >30 or <18 kg/m2, as well as
diseases and treatments that interfere with bone metabolism
(including bisphosphonate for more than 1 year or
strontium ranelate, in the immediately preceding year).
The protocol was approved by local ethics committees and
complied with the ethical principles of the Declaration of
Helsinki, 1964, revised in Tokyo 2004. All participants
gave their written informed consent prior to their participa-
tion. The trial was registered with www.controlled-trials.
com as ISRCTN82719233.
Participants were randomly assigned to either stron-
tium ranelate (2 g/day; 1 sachet/day at bedtime, plus 1
capsule placebo/week in the morning) or alendronate
70 mg/week (1 capsule/week in the morning, plus 1
sachet placebo/day at bedtime). The treatments and
placebo were similar in terms of appearance, and sachet
or capsule weight. All patients received additional
calcium (500 mg) and vitamin D (400 IU) supplements
(1 tablet/day at lunchtime).
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The primary endpoints of this exploratory study were
HR-pQCT parameters (all parameters measured at cortical
and trabecular level, described below). Secondary criteria
were FEA parameters, lumbar and femoral neck aBMD,
markers of bone resorption and formation as well as safety.
HR-pQCT analysis
HR-pQCT (XtremCT, Scanco Medical AG, Bruttisellen,
Switzerland) examinations were performed on the non-
dominant distal tibia and distal radius at baseline, 3 and
6 months, and then every 6 months up to 2 years, as
previously described [20]. The region of interest consisted
of 110 slices measured proximally to a 22.5-mm point from
the distal joint limit for the tibia, and a 9.5-mm point from
the most proximal location of the subchondral plate for the
radius. Scans were analyzed in a central facility (Scanco
Medical) by assessors blinded to the treatment assignment.
A scan was considered as assessable if it was rated as being
of a very good or good quality (i.e., without movement
artifacts, or minor movements that did not affect the
integrity of the cortical circumference). This was the case
for 96% of examinations at the distal tibia and 77% at the
distal radius. Quality control was centrally reviewed on a
daily basis, and devices were cross-calibrated with a density
phantom and an anthropomorphic phantom.
HR-pQCT data were processed as described [5, 20–22].
The parameters reported were cortical bone density (DCort,
cortical volumetric BMD), cross-sectional area (CSA),
cortical thickness (CTh, mean cortical volume divided by
the outer bone perimeter), cortical porosity, trabecular bone
density (Dtrab, trabecular volumetric BMD), bone volume
fraction (BV/TV, trabecular bone volume to tissue volume,
calculated using trabecular density/1200 mgHA/cm3), and
trabecular number (TbN), thickness (TbTh), and separation
(TbSp). In a second series of analysis, CTh, TbTh, and
TbSp were also measured using another software, whereby
the parameters were not derived from density, but directly
assessed using a distance transformation approach [5].
Moreover, cortical porosity was evaluated after a dual
segmentation process of the cortex, as described by
Burghardt et al. [23], and Nishiyama et al. [24]. These
analyses were a post-hoc analysis.
Finite element analysis
Finite element meshes of the tibia were generated directly
from binary or gray-level HR-pQCT images by the voxel
conversion approach [25], using Image Processing Lan-
guage (IPL) software (Scanco Medical). Linear FEA was
applied to simulate a uniaxial compression test in the axial
direction using the FE-solver included in the IPL software
v1.12. Material properties chosen were isotropic and elastic
for both models, with a Poisson’s ratio of 0.3. For the
segmented model, cortical and trabecular bone elements
were distinguished using the standard HR-pQCT protocol
and assigned different elastic properties: Young’s modulus
was 20 and 17 GPa for cortical and trabecular bone,
respectively. For the continuum model, trabecular and
cortical bone were treated in the same way and the gray-
level images were binned to 8-bit data, thus allowing 127
different moduli, calculated, based on the relation devel-
oped by Homminga et al. [26] and MacNeil et al. [14]. For
the translation of density to elastic modulus, we used the
equation:
Eelement ¼ Etissue  Gray valueelementð Þg ;
where the gray-value data was normalised to 900 mg HA/
cm3, γ was set at 1.1, and negative moduli were removed.
Analyses were performed blinded to treatment allocation.
Failure load (N) was estimated in the segmented model
based on Pistoia’s criterion assuming that fracture occurs
when 2% of the bone tissue is strained beyond a critical limit
of 7,000 μstrain with elastic properties of 10 GPa [13, 27].
However, since the elastic properties in our study were twice
as high as those used by Pistoia et al., the critical strain limit
in our study was set to 3,500 μstrain in order to calculate
comparable failure loads. Stiffness (kN/mm) was assessed
with both models. Average values of the von Mises stresses
in the trabecular and cortical bone (MPa), which are a
measure of the intensity of the internal forces as a reaction to
external loading applied on the bone, were computed in the
segmented model for a 1,000 N applied load. The polar
moment of inertia was calculated as well [28].
Other measurements
Lumbar spine and femoral neck aBMD were measured at
baseline, and after 1 and 2 years with dual-energy X-ray
absorptiometry (DXA) using Hologic or Lunar devices.
Devices were cross-calibrated with an external phantom
(European spine phantom; QRM GmbH, Möhrendorf, Ger-
many) to optimize concordance between the centers. Bio-
chemical bone turnover markers were obtained at each visit
and were centrally assessed (Supreme, Liège, Belgium).
Bone-specific Alkaline Phosphatase (bALP) was assayed by
an immunoradiometric assay (Tandem® ROstase®, Beckman
Coulter, San Diego, CA, USA) and S-CTX-I by an enzyme-
linked immunosorbent assay (Serum CrossLaps® ELISA,
Nordic Bioscience Diagnostic, Herlev, Denmark). Adverse
events and laboratory parameters were recorded at each visit.
Statistical methods
In this exploratory study, all efficacy analyses were
performed in the intention-to-treat (ITT) population (all
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randomized patients who had taken at least one dose of
study medication and had a baseline and post-baseline
assessable by HR-pQCT scan) on non-corrected and non-
calibrated data. The safety set was defined as all included
patients who took at least one dose of the study treatment.
All the analyses described herein were preplanned, and the
blinding was not broken for the investigators, the patients,
or the sponsor at the time of the interim analysis after 1 year
[20].
Baseline characteristics are presented as descriptive
statistics. Relative change from baseline to last observation
was analyzed using a linear model with center as covariate
(fixed effect), and robustness was checked with center as a
random effect. A second robustness analysis was performed
using a nonparametric approach without adjustment, based
on Hodges–Lehmann’s estimator. Treatment effect was
analyzed using a Student t-test or a Wilcoxon signed-
ranks test, and treatment groups were compared using
Student t-test on the overall general linear model (least-
squares norm) or a Mann–Whitney–Wilcoxon test when
appropriate. Within-group results are presented as means ±
SD, or medians when non-normally distributed, and each
between-group difference is presented as an estimate
(standard error [SE]) with 95% confidence interval (CI).
Similar analyses were performed for aBMD and bone
turnover markers. Safety data are presented as descriptive
statistics. The type I error rate was set at 5%. All statistical
analyses were performed on SAS® version 9.1 software.
Results
Figure 1 shows the trial profile. Between January 2006 and
February 2007, we randomly allocated 88 patients to
strontium ranelate (n=46) or alendronate (n=42) (i.e., the
safety set). The ITT population comprised 83 patients (96%
of the randomized population; n=42 strontium ranelate; n=
41 alendronate). Thirty-one patients left the study; the
distribution of withdrawals was well balanced between the
groups, and the majority of patients left the study for non-
medical reasons. The baseline characteristics of the ITT
population are presented in Table 1. There were no relevant
differences in demographic, clinical, or HR-pQCT charac-
teristics between the treatment groups. Nearly 25% of the
patients had previous osteoporotic peripheral fracture (n=
10 strontium ranelate; n=11 alendronate) or vertebral
deformities (n=7 strontium ranelate; n=9 alendronate).
Mean treatment duration in the safety set was 19.5±
6.8 months (range 1–25 months). The baseline character-
istics of the fully completers were identical to those of the
ITT population (data not shown). Overall compliance
during the 2 years of the study was 90% for sachets and
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Fig. 1 Trial profile. HR-pQCT, high-resolution peripheral quantitative computed tomography
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93% for capsules. The compliance was defined as the
number of sachets or capsules taken divided by the
theoretical number of sachets or capsules to be taken.
Relative changes in HR-pQCT parameters at last value
versus baseline for distal tibia are summarized in Table 2.
There were 41 patients with assessable scans at baseline and
post-baseline in the strontium ranelate group versus 39 in the
alendronate group. Distal tibia cortical parameters CTh and
DCort increased from baseline to last value with strontium
ranelate with relative changes of 6.3% and 1.4% (P<0.0001
and P<0.005, respectively) versus no change with alendro-
nate (0.9% and 0.4%, respectively; both NS). There was a
between-group difference for both CTh (P<0.005) and DCort
(P<0.05). For CTh directly measured using a distance
transformation method, the between-group difference of
changes from baseline to last value was of lower magnitude,
with a P value close to significance (P=0.060). The between-
group change difference was 2.2±2.2% (P=0.316, NS).
For trabecular bone, as assessed with the standard
software, the relative change in BV/TV was 2.5% with
Table 1 Baseline characteristics of the intention-to-treat (ITT) population
Strontium ranelate (n=42) Alendronate (n=41) Whole population (n=83)
Demographic characteristics
Age (years) 63.6±7.5 63.8±7.6 63.7±7.5
Weight (kg) 59.1±9.1 56.5±7.6 57.8±8.5
BMI (kg/m²) 23.1±3.3 22.6±2.7 22.9±3.1
DXA-BMD and T-score
L1–L4 aBMD (g/cm²) 0.748±0.087 0.735±0.093 0.741±0.089
Lumbar spine T-score −2.7±0.8 −2.8±0.8 −2.8±0.8
Femoral neck aBMD (g/cm²) 0.619±0.097 0.609±0.094 0.614±0.095
Femoral neck T-score −2.0±0.8 −2.1±0.8 −2.0±0.8
HR-pQCT parameters (distal tibia)
DCort (mg HA/cm
3) 750.3±87.6 745.7±78.1 748.1±82.6
CTh (μm) 721±242 753±263 737±251
Cortical porosity (%) 8.9±3.5 9.2±2.8 9.1±3.1
BV/TV (%) 9.5±2.5 9.3±2.7 9.4±2.6
TbN (mm−1) 1.35±0.34 1.25±0.29 1.30±0.32
TbSp (μm) 686±269 713±190 699±233
TbTh (μm) 69±15 73±17 71±16
CSA (mm2) 835±152 820±161 828±157
Polar moment of inertia (mm4) 15,481±3,505 13,865±2,909 14,693±3,214
HR-pQCT parameters (distal radius)
DCort (mg HA/cm
3) 790.0±92.7 782.9±92.2 786.8±91.9
CTh (μm) 595±176 559±189 579±182
Cortical porosity (%) 4.6±2.2 4.8±1.9 4.7±2.0
BV/TV (%) 8.7±2.7 7.9±2.2 8.3±2.5
TbN (mm−1) 1.40±0.31 1.29±0.27 1.35±0.30
TbSp (μm) 651±199 697±192 671±195
TbTh (μm) 60±12 59±11 60±12
CSA (mm2) 457±84 418±83 440±84
Polar moment of inertia (mm4) 3,326±735 2,986±744 3,177±739
FEA analysis (segmented model, distal tibia)
Failure load (N) 6,715±947 6,581±874 6,649±909
Stiffness (kN/mm) 311±49 304±49 307±49
Cortical stress (MPa) 7.13±1.33 7.21±1.06 7.17±1.20
Trabecular stress (MPa) 3.82±0.67 4.03±0.52 3.92±0.61
Values are mean ± SD
BMI body mass index, aBMD areal bone mineral density (DXA-BMD), CSA cross-sectional area, BV/TV bone volume fraction, CTh cortical
thickness, DCort cortical bone density, Dtrab trabecular bone density, HR-pQCT high-resolution peripheral quantitative computed tomography, TbN
trabecular number, TbSp trabecular separation, TbTh trabecular thickness using standard software
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strontium ranelate from baseline to last value (P<0.0001)
versus 0.8% with alendronate (NS), with a significant
between-group difference (P<0.05). TbN significantly
increased by last value in both groups with a relative
change of 3.6% with strontium ranelate and 4.6% with
alendronate (both P<0.05 versus baseline). TbSp decreased
with a relative change of −3.0% with strontium ranelate and
−3.6% with alendronate (both P<0.05 versus baseline),
while TbTh remained unchanged with strontium ranelate
(−0.5%, NS) and decreased with alendronate (−3.0%, P<
0.05). TbN, TbSp, and TbTh analysis by distance transfor-
mation provided qualitatively similar results to those
obtained with the standard software.
Figure 2 presents the progression of distal tibia CTh and
BV/TV throughout the study. Progressive increases were
recorded in both parameters with strontium ranelate from
the third month onward. The changes of CTh and BV/TV
from baseline with strontium ranelate were significant from
the third month onward for CTh and from the sixth month
onward for BV/TV. The change from baseline with
strontium ranelate was significantly different from that with
alendronate after 3 months, 1 year, and 2 years.
The number of assessable scans for the distal radius was
lower (36 in the strontium ranelate group and 28 in the
alendronate group) than for the distal tibia. This was mainly
due to a higher number of scans with movement artifacts. The
changes in HR-pQCT parameters for the distal radius were
smaller (Table 2). At last value, distal radius DCort increased
with a relative change of 1.1% with strontium ranelate (P<
0.05 versus baseline), but not with alendronate (−0.3%, NS),
Table 2 High-resolution peripheral quantitative computed tomography HR-pQCT results
Relative change from baseline for last
value (%)
Between-group difference
Strontium ranelate
(n=42)
Alendronate
(n=41)
E (SE), 95% CI P value†
Distal tibia
Patients with assessable scans at baseline and post-baseline 41 39
DCort 1.4±2.8** 0.4±2.1 1.1 (0.5), 0.1 to 2.2 <0.05
CTh 6.3±9.5**** 0.9±6.2 5.4 (1.8), 1.8 to 9.1 <0.05
[2.1±3.1] [0.6±4.2] [1.6 (0.8), −0.7 to 3.2] 0.06
BV/TV 2.5±5.1**** 0.8±3.8 1.8 (0.9), 0.1 to 3.5 <0.05
TbN 3.6±9.3* 4.6±10.0* −1.1 (2.1), −5.2 to 3.1 0.61
[3.5±9.2] [4.6±10.0] [−1.1 (2.1), −5.3 to 2.9] 0.58
TbSp −3.0±8.7* −3.6±9.7* 0.7 (2.0), −3.2 to 4.7 0.72
[−2.5±8.5] [−3.2±9.5] [0.8 (2.0), −3.1 to 4.7] 0.70
TbTh −0.5±8.7 −3.0±8.1* 2.6 (1.9), −1.2 to 6.4 0.18
[+0.3±2.0] [−0.4±1.7] [0.7 (0.4), −0.1 to 1.5] 0.09
Cortical porosity 3.8±12.1 1.4±7.0 2.2 (2.2), −2.1 to 6.6 0.31
Polar moment of inertia 1.8±3.3 0.5±3.9 1.4 (0.8), −0.2 to 3.0 0.09
Distal radius
Patients with assessable scans at baseline and post-baseline 36 28
DCort 1.1±2.5 −0.3±1.9 1.2 (0.5), 0.1 to 2.2 <0.05
CTh 0.8±6.6 −1.0±7.2 1.2(1.6), −2.0 to 4.3 0.46
BV/TV 0.0±4.1 −1.4±4.7 1.7 (1.0), −0.2 to 3.6 0.07
TbN 0.3±5.7 −1.3±4.9 1.3 (1.6), −1.4 to 4.1 0.33
TbSp 0.01±6.2 1.6±5.2 −1.3 (1.5), −4.2 to 1.7 0.39
TbTh −0.1±6.0 −0.2±6.3 0.8 (1.3), −1.9 to 3.5 0.56
Cortical porosity 0.1±12.0 0.7±9.5 −0.5 (2.9), −6.3 to 5.2 0.85
Polar moment of inertia −0.4±2.9 −0.3±3.1 −0.4 (0.7), −1.7 to 1.0 0.61
Values are means ± SD. The values were obtained with the standard software. In brackets are the results obtained with the direct transformation
software
E (SE) estimate of the adjusted mean difference (standard error), CI confidence interval of estimate
†P value for between group difference strontium ranelate versus alendronate (parametric approach)
*P<0.05, **P<0.005, ***P<0.0005, ****P<0.0001 last value versus baseline (two-sided Student’s t-test for paired samples)
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with a significant between-group difference (E [SE], 1.2
[0.5], 95% CI, 0.1–2.2, P<0.05). There were no other
statistically different relative changes in the other parameters
for distal radius over time or between the groups.
FEA results in the ITT population (41 patients for
strontium ranelate and 39 for alendronate) are presented in
Fig. 3 for failure load, and for trabecular and cortical stresses
in the segmented model. Failure load increased with
strontium ranelate with a relative change of 2.1% at last
value (P<0.005 versus baseline) versus no change with
alendronate (−0.6%, NS). This led to a significant between-
group difference in failure load (P<0.01). Treatment with
strontium ranelate was associated with lower trabecular and
cortical stresses, with relative changes of −2.4% (P<0.005
versus baseline) and −1.6% (P<0.05 versus baseline),
respectively. Trabecular stress decreased with alendronate
(relative change, −2.0%, P<0.01 versus baseline), but
cortical stress did not (relative change 1.0%, NS). There
was therefore a significant between-group difference for
cortical stress (P<0.05), but not for trabecular stress.
Depending on the segmented or gray-level μFEA model
applied, stiffness was either maintained (relative change
1.2%, P=0.074) or increased (3.1%, P<0.001) with stron-
tium ranelate, and decreased (−1.7%, P<0.05) or maintained
(0.7%, NS) with alendronate. For both models, a between-
group difference was observed for stiffness (P<0.05 for
both). The difference in polar moment of inertia between last
measurement and baseline was 1.8±3.3% and 0.5±3.9% for
strontium ranelate and alendronate, respectively, with a
between-group difference of 1.4±0.8% (P=0.095).
Mean lumbar spine aBMD increased in all patients, by 6.5±
6.3% with strontium ranelate and 5.6±4.3% with alendronate.
Femoral neck BMD increased as well (4.7±4.3% and 3.3±
4.0%, respectively). The increase in lumbar spine and femoral
neck BMDover timewas statistically significant in both groups
(all P<0.0001), without any between-group difference.
The changes in bone turnover markers are presented in
Fig. 4. Both agents reduced S-CTX-I from the third month
of treatment, with larger reductions for alendronate. The S-
CTX-I values were significantly different from baseline by
3 and 6 months (P<0.05), 18 and 24 (both P<0.005) with
strontium ranelate and at all time-points with alendronate
(all P<0.0001). By 2 years, the median change from
baseline was −16% and −59% for strontium ranelate and
alendronate, respectively. In contrast, b-ALP increased from
the third month with strontium ranelate, with significant
changes by months 3, 18 (P<0.005) and 24 (median change
+18%, P<0.0005). At all time points the decrease in b-ALP
was significant with alendronate (all P<0.0001), with a
median change from baseline to last value of −31%. The
between-group difference was significant for both markers
at all time points (all P<0.001).
The rate of treatment-related emergent adverse events
was similar in both groups (16 with strontium ranelate and
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14 with alendronate), and these events were most frequently
related to gastrointestinal disorders (7 and 10, respectively).
Adverse events leading to premature treatment withdrawal
occurred in 11 patients (seven with strontium ranelate and
four with alendronate). Two of these events in the strontium
ranelate group were related to cutaneous disorders (pruritic
rash and rash, both of mild intensity) and one event to a
vascular disorder (superficial phlebitis of mild intensity).
Three of the events in the alendronate group were related to
gastrointestinal disorders (nausea, upper abdominal pain,
and peptic ulcer, of moderate intensity for all three). There
were no clinically relevant changes over time or between-
group difference in laboratory values or vital signs.
Discussion
This HR-pQCT study indicates that treatment with stron-
tium ranelate is associated with changes in distal tibia
cortical and trabecular structure and density, i.e., significant
increases in cortical thickness, cortical and trabecular bone
density. These changes were already detected by 3 months
of treatment and continued up to 2 years. Alendronate
maintained these bone parameters at their initial level.
Trabecular number increased with both treatments (without
any difference between groups), whereas trabecular separa-
tion decreased. There was no change in trabecular thickness
with strontium ranelate but a decrease with alendronate.
Our 2-year results extend and consolidate the 1-year
results in the same population [20], and demonstrate that
the differences between the two treatments continue to
increase beyond 1 year. Our analysis also indicates that the
changes in bone microstructure with strontium ranelate
parallel higher failure load, lower cortical and trabecular
stresses, an increase in lumbar and femoral neck DXA-
determined aBMD together with a modest increase in the
bone-formation marker bone specific alkaline phosphatase
and a decrease in the bone resorption marker CTX.
A possible influence of edge detection artifacts on our
findings was extensively discussed in the report of the 1-
year results of this trial [20]. Such an influence could
potentially affect both HR-pQCT and FEA parameters, and
could be a concern in both arms of our study. Indeed, both
strontium having an atomic number of twice that of
calcium, and alendronate associated with a higher mean
degree of mineralization could influence x-ray attenuation
[29]. However, bone strontium content is low after 2 years
of treatment (about 1%). Based on bone strontium content
estimation and theoretical calculations, such an amount
may contribute to an overestimation of cortical thickness by
around 2% [30]. On the other hand, there was no
correlation between distal tibia cortical thickness and serum
strontium levels (R2=0.17, P=0.292). By the third month of
treatment, when some structural changes were already
detected, bone strontium content was considerably lower
than 1%, reducing thereby the likelihood that the changes
observed were entirely due to strontium in bone [20]. By
3 months, cortical density between-group difference was
0.5 (0.3) [0.0; 1.1], P=0.04, and 0.2 (0.3) [−0.4; 0.7], P=
0.6 (mean SE) [95% CI] at distal tibia and distal radius,
respectively. Furthermore, when HR-pQCT values were
obtained using a distance transformation method, hence
with parameters less influenced by density, difference
between both groups was of lower magnitude, but close
to significance (P=0.060). However, an increase in cortical
thickness could result from an increase in cortical area as
the result from a reduction in cortical porosity. Indeed, the
cortical compartment comprises mineralized matrix and
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pores. If porosity is reduced, as for instance by filling the
holes with mineralized bone, the cortical compartment will
thus increase [31]. However, the evaluation of cortical
porosity did not support this hypothesis.
Our results are in agreement with previous μCT analyses
of 41 biopsies from SOTI and TROPOS trials, which
reported increased cortical thickness (P=0.008) and de-
creased trabecular separation (P=0.041) with strontium
ranelate versus placebo over 3 years, but no significant
change in BV/TV [17]. Another biopsy study performed in
ten patients previously treated with bisphophonates, who
had paired biopsies before and after 1 year of strontium
ranelate treatment, has demonstrated a significant increase
in relative bone volume, as assessed by histomorphometry,
a technique which is not influenced by the presence of
strontium in bone [32].
The results for alendronate in this study contrast with
recent HR-pQCT results, which indicate an increase in
cortical thickness versus placebo with alendronate, and
no change in trabecular number, thickness, and separa-
tion [33, 34]. Recent studies have reported increased
BMD with bisphosphonate treatment, as measured by
QCT or HR-pQCT (at the radius and tibia for alendronate;
and at total hip for ibandronate) [31, 33, 34]. Regarding
the groups treated with alendronate, the patients in our
study were older, had slightly lower lumbar spine aBMD,
and received less vitamin D. These discrepancies highlight
the need for further HR-pQCT analyses or biopsy studies
with bisphosphonates. Regarding bone anabolic agents,
the only published report to date failed to find clear HR-
pQCT changes in bone structure in patients receiving
teriparatide [35], while other histomorphometric and μCT
evidences have demonstrated anabolic effects of teripara-
tide [36–38]. This was attributed in part to the fact that the
majority of the study population had previously received
bisphosphonate therapy (ten out of 11 patients), which
may have blunted the bone response to an anabolic agent
[35].
We used FEA based on binary and gray-level HR-pQCT
images to estimate failure load, cortical and trabecular
stresses, and stiffness of treated bone. As emphasized by
Burghardt et al. [33], the use of FEA based on binary HR-
pQCT data helps to understand how microstructural
changes in response to treatment affect biomechanical
parameters, but fails to indicate changes in mineral
composition, which, supposedly, are a significant factor in
the anti-fracture efficacy of anti-resorptive therapies. How-
ever, one limitation of the gray-level model is that the exact
relationship between the element gray-value and the
element elastic modulus is presently not available for the
tibia. Therefore, we do not have any information in human
on the influence of strontium on this analysis. Our results
indicate that treatment with strontium ranelate is associated
with greater failure load and lower cortical stress than
alendronate. Both treatments improved trabecular stress.
Depending on the model applied, stiffness was either
maintained or increased with strontium ranelate, and
maintained or decreased with alendronate. These results
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also compare well with those reported for ibandronate,
which increased trabecular parameters but not cortical
parameters [31], as well as with those reported for
alendronate showing no significant difference in tibial
stiffness and failure load after 2 years of treatment [33].
The impact of strontium ranelate on cortical bone is of
particular interest, since recent findings suggest that cortical
bone may be a more important target for the treatment of
osteoporosis than previously thought [39, 40]. Both agents
reduce fracture risk, whereas only strontium ranelate
improves FEA parameters. We could, therefore, hypothesize
that alendronate’s anti-fracture efficacy may be related to a
modification of bone metabolism and a change in the
intrinsic matrial properties of bone in terms of mineraliza-
tion and aBMD [29]. In an experimental study, FEA was
applied to the vertebral body of rats treated with strontium
ranelate for 2 years [41]. FE simulations showed a 29%
higher strength and a 22% higher stiffness with strontium
treatment, which were related to greater cortical and
trabecular thickness, together with a 7% decrease in tissue
level stresses. Thus, these experimental data are in
agreement with those of the present study in human. On
the other hand, while strontium ranelate’s anti-fracture
efficacy is linked to an increase in aBMD [42], the
improvement in structure would contribute to a higher
resistance to fracture. The increases in lumbar spine and
femoral neck BMD are in line with the results of phase 3
studies with both agents [15, 16, 18].
The possibility of edge detection artifacts as described
above and the sample size limit our study. Another
limitation is the lack of clear differences at the distal
radius, due to difficulties in measurement (28% of radius
images were not readable, mainly due to movement
artifacts) and the small effect sizes at this site. The absence
of effect may also be related to the fact that radius is not a
weight-bearing bone, with possibly different bone turnover
responses. In this context, we should note that the change in
aBMD at the radius level is usually smaller than at other
sites, regardless of the anti-osteoporotic treatment. This
appears to complicate detection of changes in structure at
this site. The distal tibia, however, has been shown to be a
relevant site since distal tibia HR-pQCT values are
associated with fractures to the same extent as at the radius
[43]. This selective difference in structural responses
between distal radius and tibia is puzzling, and could even
support that the changes observed at the tibia level cannot
solely be attributed to strontium-mediated edge detection
modification. Indeed, at both skeletal sites, the increase
with strontium ranelate in cortical volumetric density was
identical, implying that the structural variables should be
similarly influenced. However, this is not the case, since
there was an increase in CTh at tibia, but not at radius
levels.
Within the constraints of the method, and while a
possible artefactual contribution of strontium cannot be
quantified, altogether our results are compatible with
strontium ranelate-mediated changes in distal tibia bone
structure as assessed with HR-pQCT and FEA-
determined biomechanically relevant parameters, greater
than with alendronate. However, the magnitude of the
differences is unclear and requires confirmation with
another method.
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